Photo Rounds

Umbilicated cheek lesion

A 79-year-old man presented to the family medicine skin clinic so that his physician could check on the healing of a recently treated basal cell carcinoma (BCC). During the visit, the patient asked the physician to look at an asymptomatic lesion on his right cheek. The patient’s past medical history was unremarkable except for nonmelanoma skin cancer (NMSC) and actinic keratoses. The physical exam revealed an umbilicated 4-mm lesion with prominent blood vessels.

What’s your diagnosis?


 

References

Umbilicated cheek lesion

Dermoscopy revealed multiple small white structures around a central pore and tortuous, but not arborizing, blood vessels around the periphery (frequently called a crown pattern). These features pointed to the diagnosis of sebaceous gland hyperplasia (SGH).

SGH is a common benign condition seen predominantly in middle- to older-age people and patients on immunosuppressant drugs (especially ciclosporin). SGH tends to manifest as multiple lesions on the face and forehead, although the lesions can appear elsewhere.1

As the name implies, SGH is hyperplasia of the sebocytes of the hair follicle, which results in white-to-yellow clusters around the dilated opening of the follicle.1 In contrast to BCCs, which have arborizing blood vessels that can occur throughout the lesion, the vessels in SGH have a lower propensity for branching and tend to follow the periphery instead of crossing into the central pore.2 This characteristic pattern, as well as the appearance of multiple similar lesions elsewhere on a patient’s body, suggests a diagnosis of SGH. If the lesion is atypical, solitary, or has other features that make the diagnosis uncertain, a biopsy is recommended.

SGH is not malignant and is asymptomatic, so treatment is not required. However, the cosmetic appearance can be distressing or undesirable for some patients.1 The most common cosmetic remedies are destructive and include electrodessication, cryosurgery, and treatments with laser and intense pulsed light. Unfortunately, if there is residual tissue after treatment, recurrence is common, and due to the destructive nature of treatment, scarring is possible. It is important to counsel the patient regarding both of these possibilities and to balance the extent of destruction.

In patients with multiple lesions, oral isotretinoin may be used, but SGH will recur if treatment is discontinued. Additionally, isotretinoin, which is also used for cystic acne, is a high-risk medication due its potential to cause fetal anomalies and death if used during pregnancy. Patients usually get cheilitis and dyshidrosis due to its drying effect, but those symptoms are manageable with topical emollients.

This patient declined treatment, as he already had scars from previous NMSCs and was not concerned about the appearance of SGH.

Photo courtesy of Daniel Stulberg, MD. Text courtesy of Daniel Stulberg, MD, FAAFP, Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque.

Recommended Reading

Infant with mottled skin
MDedge Family Medicine
‘Genetic’ height linked to peripheral neuropathy and certain skin and bone infections
MDedge Family Medicine
Therapeutic patient education can help with adherence to treatment
MDedge Family Medicine
Atopic dermatitis: Options abound, and more are coming
MDedge Family Medicine
FDA cautions against using OTC products to remove skin spots, moles
MDedge Family Medicine
Current monkeypox outbreak marked by unconventional spread, clinical features
MDedge Family Medicine
Coalescing skin-colored papules
MDedge Family Medicine
FDA OKs first systemic treatment for alopecia areata
MDedge Family Medicine
A fish tale? More on that seafood, melanoma study 
MDedge Family Medicine
Hair disorder treatments are evolving
MDedge Family Medicine